Answers are grounded in this paper and cite their sources.
Purpose In low- and middle-income settings where NK1 receptor antagonists are often unaffordable, we evaluated the interaction and efficacy of add-on olanzapine plus pregabalin for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Methods In this single-center 2 × 2 factorial, double-blind, add-on placebo-controlled trial, 104 participants receiving HEC were randomly assigned 1:1:1:1 to olanzapine 5 mg, pregabalin 75 mg, their combination, or placebo once daily for 4 days, with standard ondansetron and dexamethasone. The primary outcome was the olanzapine × pregabalin interaction on the mean 5-day Visual Analog Scale (VAS) nausea score. Secondary outcomes included no nausea, no significant nausea (VAS < 2.5), no vomiting, complete response/control, Functional Living Index–Emesis, and adverse events. Clinical-trial simulation explored the interaction at larger n and identified minimum effective doses. Results No significant olanzapine × pregabalin interaction was detected on mean VAS (coefficient, 0.44 [95% CI, –0.89 to 1.77]; P = .52); effects were consistent with additivity at the trial sample size. Simulation at n ≥ 600 suggested a small antagonistic term, interpreted as hypothesis-generating. The combination arm had the lowest overall 5-day VAS (0.89, standard deviation [SD], 1.07) versus placebo (3.68, SD 2.06; analysis of variance P < .001); secondary outcomes favored the combination and are reported as hypothesis-generating. Emax modeling supports a future dose-reduced regimen of olanzapine 5 mg + pregabalin 50 mg once daily or olanzapine 2.5 mg + pregabalin 75 mg once daily to preserve efficacy while reducing toxicity. Sedation and dizziness were more frequent in the study-drug arms. Conclusion In patients receiving HEC, add-on olanzapine 5 mg + pregabalin 75 mg once daily improved nausea control versus placebo, with effects consistent with additivity. No synergy was demonstrated; the simulation-based antagonism signal warrants confirmation, and a dose-reduced combination is proposed for future evaluation.
No takes yet. Share an insight, caveat, or question.
Ramasubbu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: